JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

2.37 -3.27

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.35

Máximo

2.45

Métricas clave
By Trading Economics
Ingresos	-1.6M -38M
Ventas	1.6M 11M
Margen de beneficios	-333.127
Empleados	144
EBITDA	-1.8M -35M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+316.33% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	73M 568M
Apertura anterior	5.64
Cierre anterior	2.37

Noticias sobre sentimiento de mercado

By Acuity

62%

38%

316 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 nov 2025, 21:44 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov 2025, 23:28 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov 2025, 23:24 UTC

Ganancias

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:14 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

3 nov 2025, 23:14 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov 2025, 23:12 UTC

Ganancias

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov 2025, 23:06 UTC

Charlas de Mercado

Ganancias

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov 2025, 22:36 UTC

Charlas de Mercado

Ganancias

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov 2025, 22:24 UTC

Charlas de Mercado

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov 2025, 21:59 UTC

Charlas de Mercado

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado

Ganancias

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

3 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 nov 2025, 21:49 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov 2025, 21:40 UTC

Ganancias

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov 2025, 21:31 UTC

Charlas de Mercado

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov 2025, 21:19 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov 2025, 21:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov 2025, 21:11 UTC

Ganancias

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov 2025, 21:07 UTC

Ganancias

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov 2025, 21:05 UTC

Ganancias

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:05 UTC

Ganancias

Palantir Technologies 3Q Net $475.6M >PLTR

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

316.33% repunte

Estimación a 12 Meses

Media 10.2 USD 316.33%

Máximo 15 USD

Mínimo 8 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

316 / 373 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.